Noteworthy in this context though is the newly FDA approved bispecific T-cell engager, tebentafusp, which is used in unresectable/metastatic uveal melanoma and targets the melanoma-associated antigen (gp100) (48). The gene discussed is PMEL; the disease is uveal melanoma.